Type 1 Diabetes & CBD

Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through cyclooxygenase activation.

Posted by Joe Pavlik on

Published: J Pharmacol Exp Ther. 2014 Nov;351(2):457-66. doi: 10.1124/jpet.114.217125. Epub 2014 Sep 11. Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through cyclooxygenase activation. Wheal AJ, Cipriano M, Fowler CJ, Randall MD, O'Sullivan SE. Abstract Cannabidiol (CBD) decreases insulitis, inflammation, neuropathic pain, and myocardial dysfunction in preclinical models of diabetes. We recently showed that CBD also improves vasorelaxation in the Zucker diabetic fatty (ZDF) rat, and the objective of the present study was to establish the mechanisms underlying this effect. Femoral arteries from ZDF rats and ZDF lean controls were isolated, mounted on a myograph, and incubated with CBD (10...

Read more →

Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes.

Posted by Joe Pavlik on

Published: Clin Hemorheol Microcirc. 2016 Oct 18. Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. Lehmann C, Fisher NB, Tugwell B, Szczesniak A, Kelly M, Zhou J. Abstract BACKGROUND: Destruction of the insulin-producing beta cells in type 1 diabetes (T1D) is induced by invasion of immune cells causing pancreatic inflammation. Cannabidiol (CBD), a phytocannabinoid, derived from the plant, Cannabis sativa, was shown to lower the incidence of diabetes in non-obese diabetic (NOD) mice, an animal model of spontaneous T1D development. OBJECTIVE: The goal of this study was to investigate the impact of experimental CBD treatment on early...

Read more →